Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
337
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
+3.29M
-
Total reported value, excl. options
-
$4.83B
-
Value change
-
+$122M
-
Put/Call ratio
-
0.43
-
Number of buys
-
170
-
Number of sells
-
-167
-
Price
-
$39.54
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2022
401 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2022.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 337 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
of 124M outstanding shares and own 98.75% of the company stock.
Largest 10 shareholders include BlackRock Inc. (18.2M shares), VANGUARD GROUP INC (13.3M shares), STATE STREET CORP (6.17M shares), Artisan Partners Limited Partnership (6.13M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (4.44M shares), SNYDER CAPITAL MANAGEMENT L P (4.42M shares), JPMORGAN CHASE & CO (3.93M shares), GEODE CAPITAL MANAGEMENT, LLC (2.48M shares), GW&K Investment Management, LLC (2.2M shares), and LOOMIS SAYLES & CO L P (2.15M shares).
This table shows the top 337 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.